Medtronic Shares Are Trading Lower After the Company Announced the Six-month Results From the Full Cohort of the SPYRAL HTN-ON MED Trial. For the Primary Endpoint, RDN Did Not Demonstrate a Statistically Significant Reduction.
Medtronic Shares Are Trading Lower After the Company Announced the Six-month Results From the Full Cohort of the SPYRAL HTN-ON MED Trial. For the Primary Endpoint, RDN Did Not Demonstrate a Statistically Significant Reduction.
美敦力公司公佈了SPYral HTN-on MED試驗的全部六個月結果後，美敦力的股價下跌。對於主端點，RDN沒有顯示出統計意義上的顯著減少。
Medtronic shares are trading lower after the company announced the six-month results from the full cohort of the SPYRAL HTN-ON MED trial. For the primary endpoint, RDN did not demonstrate a statistically significant reduction.
美敦力公佈了SPYral HTN-on MED試驗的全部隊列6個月的結果後，該公司股價走低。對於主要終點，RDN沒有顯示出統計上顯著的減少。
資訊熱榜
更新時間